Skip To Main Content
Carrie Pallardy on Muck Rack

Carrie Pallardy

Verified
Chicago
As seen in: MSN, Chicago Tribune, Investopedia, SearchCIO, TechTarget Japan, InformationWeek, CSO, The Code Project, Fort Worth Star-Telegram, Matador Network and
Freelance Writer and Editor
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Carrie

Contact Carrie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mozilla report reveals wide privacy gaps among popular period tracking apps

|
By Carrie Pallardy Verified
| Digital Health Insights
Period tracking apps are popular digital health tools with global user count estimated to be over 250 million. Hundreds of different apps help users track their menstrual cycles to better understand their bodies, learn about symptoms and support their efforts to get pregnant. Women enter sensitive health information to get the benefits of these apps, which have widely varying approaches to data privacy.
Open in Who Shared Issue with article?

AI slopification: The true cost of low-quality AI implementation

|
By Carrie Pallardy Verified
| SearchCIO Verified
Understanding AI slopification Rushed AI implementation that results in low-quality output falls under the broad umbrella of the term slop. "I wanted something that stood out and got engagement. I wanted something that was exceptional. I got something average. Now, that's best case with AI slop," Tim Sanders, chief innovation officer at G2, explained.
Open in Who Shared Issue with article?

The long road to a future of AI-driven drug development

|
By Carrie Pallardy Verified
| Digital Health Insights
Pharmaceutical and biotech companies are investing billions today to get a future in which new AI drives drug discovery, trials and development, bring treatment to patients faster, safer and more affordably. Merck struck a deal with Google Cloud to leverage the tech giant’s agentic platform. Novartis, Takeda and Eli Lilly have their own big AI deals for research and drug discovery. But investment is just one piece of the puzzle.
Open in Who Shared Issue with article?
See all 1,239 licensed articles (1,241 Total)